Modified phase I of the induction regimen according to the GMALL protocol 1984. The modification consisted of a higher dose of daunorubicin (45 instead of 25 mg/m²) and the administration of asparaginase during the first 2 weeks of the protocol, and at a lower dose (2,500 instead of 5,000 U/m²). The study period was 4 weeks, starting at the first day of G-CSF administration (day 2 through 29). PRED, prednisone; ASP, asparaginase; VCR, vincristine; DNR, daunorubicin; G-CSF, granulocyte colony-stimulating factor.